TrialNature communications2025

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

Liang Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.